Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa
PURPOSEAnaplastic lymphoma kinase (ALK) gene alterations are potent oncogenic drivers in non–small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% of Asian and White patients with NSCLC have ALK-positive tumors, b...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2021-12-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO.21.00067 |
| _version_ | 1818775198868963328 |
|---|---|
| author | Abdul Rahman Jazieh Rabab Gaafar Hassan Errihani Hassan Jaafar Fouad Al Dayel Abeer A. Bahnassy Hatem El Kadi Mohamed Magdy Abdallah Ghazi Zaatari |
| author_facet | Abdul Rahman Jazieh Rabab Gaafar Hassan Errihani Hassan Jaafar Fouad Al Dayel Abeer A. Bahnassy Hatem El Kadi Mohamed Magdy Abdallah Ghazi Zaatari |
| author_sort | Abdul Rahman Jazieh |
| collection | DOAJ |
| description | PURPOSEAnaplastic lymphoma kinase (ALK) gene alterations are potent oncogenic drivers in non–small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% of Asian and White patients with NSCLC have ALK-positive tumors, but ALK rearrangement prevalence data in the Middle East and North Africa (MENA) region are limited.METHODSIn this noninterventional epidemiology study, histologically confirmed nonsquamous NSCLC samples retained for < 5 years in tissue banks at six centers in MENA were retrospectively analyzed for ALK rearrangement using the VENTANA immunohistochemistry (IHC) method. Patient characteristics obtained were analyzed for association with ALK rearrangement. Concordance between IHC and Vysis fluorescence in situ hybridization (FISH) ALK detection methods was assessed in a subset of samples.RESULTSFour hundred forty-eight tissue samples were analyzed using IHC: 137 (30.6%) in Lebanon, 104 (23.2%) in Saudi Arabia, 97 (21.7%) in Egypt, 80 (17.9%) in the United Arab Emirates, and 30 (6.7%) in Morocco. On the basis of IHC, the prevalence was 8.7% (95% CI, 6.3 to 11.7) for ALK-positivity and 91.3% (95% CI, 88.3 to 93.7) for ALK-negativity. On the basis of FISH (n = 148), the prevalence was 5.4% positivity and 81.8% negativity (12.8% nonevaluable). Concordance between IHC and FISH (n = 129) was 98.4% (95% CI, 94.2 to 99.8) for negative agreement and 98.5% (95% CI, 94.5 to 99.8) for overall agreement. Univariate analysis showed that ALK rearrangement was significantly associated with epidermal growth factor receptor wild-type status (P = .03) but was not significantly associated with sex, race, smoking history, or histologic subtype.CONCLUSIONOur findings suggest that ALK rearrangements are more prevalent in MENA than other geographic regions. High concordance was found between FISH and IHC. Except for epidermal growth factor receptor wild-type status, no clinicopathologic characteristics were associated with ALK-positive NSCLC. |
| first_indexed | 2024-12-18T10:53:14Z |
| format | Article |
| id | doaj.art-47a24cdb3f4743fc96074e03973dc6ec |
| institution | Directory Open Access Journal |
| issn | 2687-8941 |
| language | English |
| last_indexed | 2024-12-18T10:53:14Z |
| publishDate | 2021-12-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj.art-47a24cdb3f4743fc96074e03973dc6ec2022-12-21T21:10:23ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412021-12-0171556156310.1200/GO.21.00067Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North AfricaAbdul Rahman Jazieh0Rabab Gaafar1Hassan Errihani2Hassan Jaafar3Fouad Al Dayel4Abeer A. Bahnassy5Hatem El Kadi6Mohamed Magdy Abdallah7Ghazi Zaatari8King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Ministry of National Guard Hospital, Riyadh, Saudi ArabiaNational Cancer Institute, Cairo University, Cairo, EgyptNational Institute of Oncology, Mohammed V University, Rabat, MoroccoSheikh Khalifa Specialty Hospital, Ras Al Khaimah, United Arab EmiratesKing Faisal Specialist Hospital and Research Center, Riyadh, Saudi ArabiaNational Cancer Institute, Cairo University, Cairo, EgyptPfizer Inc, Africa and Middle EastPfizer Inc, EgyptAmerican University of Beirut Medical Center, Beirut, LebanonPURPOSEAnaplastic lymphoma kinase (ALK) gene alterations are potent oncogenic drivers in non–small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% of Asian and White patients with NSCLC have ALK-positive tumors, but ALK rearrangement prevalence data in the Middle East and North Africa (MENA) region are limited.METHODSIn this noninterventional epidemiology study, histologically confirmed nonsquamous NSCLC samples retained for < 5 years in tissue banks at six centers in MENA were retrospectively analyzed for ALK rearrangement using the VENTANA immunohistochemistry (IHC) method. Patient characteristics obtained were analyzed for association with ALK rearrangement. Concordance between IHC and Vysis fluorescence in situ hybridization (FISH) ALK detection methods was assessed in a subset of samples.RESULTSFour hundred forty-eight tissue samples were analyzed using IHC: 137 (30.6%) in Lebanon, 104 (23.2%) in Saudi Arabia, 97 (21.7%) in Egypt, 80 (17.9%) in the United Arab Emirates, and 30 (6.7%) in Morocco. On the basis of IHC, the prevalence was 8.7% (95% CI, 6.3 to 11.7) for ALK-positivity and 91.3% (95% CI, 88.3 to 93.7) for ALK-negativity. On the basis of FISH (n = 148), the prevalence was 5.4% positivity and 81.8% negativity (12.8% nonevaluable). Concordance between IHC and FISH (n = 129) was 98.4% (95% CI, 94.2 to 99.8) for negative agreement and 98.5% (95% CI, 94.5 to 99.8) for overall agreement. Univariate analysis showed that ALK rearrangement was significantly associated with epidermal growth factor receptor wild-type status (P = .03) but was not significantly associated with sex, race, smoking history, or histologic subtype.CONCLUSIONOur findings suggest that ALK rearrangements are more prevalent in MENA than other geographic regions. High concordance was found between FISH and IHC. Except for epidermal growth factor receptor wild-type status, no clinicopathologic characteristics were associated with ALK-positive NSCLC.https://ascopubs.org/doi/10.1200/GO.21.00067 |
| spellingShingle | Abdul Rahman Jazieh Rabab Gaafar Hassan Errihani Hassan Jaafar Fouad Al Dayel Abeer A. Bahnassy Hatem El Kadi Mohamed Magdy Abdallah Ghazi Zaatari Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa JCO Global Oncology |
| title | Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa |
| title_full | Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa |
| title_fullStr | Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa |
| title_full_unstemmed | Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa |
| title_short | Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa |
| title_sort | real world data on the prevalence of anaplastic lymphoma kinase positive non small cell lung cancer in the middle east and north africa |
| url | https://ascopubs.org/doi/10.1200/GO.21.00067 |
| work_keys_str_mv | AT abdulrahmanjazieh realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT rababgaafar realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT hassanerrihani realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT hassanjaafar realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT fouadaldayel realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT abeerabahnassy realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT hatemelkadi realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT mohamedmagdyabdallah realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica AT ghazizaatari realworlddataontheprevalenceofanaplasticlymphomakinasepositivenonsmallcelllungcancerinthemiddleeastandnorthafrica |